|
Major Member
|
引用:
|
作者中國戰螂
我沒說誰的言論沒根據啊???
貼一則你們不愛看的
巴西東南部一個擁有約4.5萬居民的小鎮塞拉納（Serrana）數月以來一直在進行一項實驗，讓所有18歲以上居民接種大陸科興疫苗。巴西目前新冠肺炎疫情仍然相當嚴重，但據稱這個小鎮的生活已經開始恢復正常。
據《華爾街日報》報導，塞拉納鎮原本是確診相當嚴重的城鎮，但衛生廳的布坦坦研究所為了要研究疫苗效果，自2月起啟動「S計劃」，為當地所有18歲以上民眾接種中國科興疫苗；鎮上居民相當期待，紛紛主動排隊參加計劃。4月時官方宣布鎮上已有27150人接種兩劑疫苗，達到目標接種人群的約97.7％。
目前鎮上單月確診數已大幅減少，在醫院排隊等待使用呼吸機的病患冗長隊伍，也已漸漸消失。有研究人員保守表示，現在就下結論為時過早，但早期結果還是相當令人振奮。報導指出，現在鎮上的孩子可以自由的在廣場奔跑，親朋好友在路上遇到也可以自在的聊...
|
https://www.pcdvd.com.tw/showpost.p...22&postcount=70
我前面的貼文裡早已經說了，中國疫苗的有效力從約50%到超過90%都有數據，你這個不就是裡面巴西的例子?
況且之前你是在說mRNA疫苗對於變異病毒效果不如滅活病毒吧？副作用也比較大？怎麼不提了？
哈佛醫學5/7的文章對於變異病毒目前兩種最主要的mRNA疫苗效用的評論:
https://www.health.harvard.edu/coro...vid-19-vaccines
沒空細翻，就是對變異病毒都有蠻高的效用，重點是最後指出，目前兩種mRNA疫苗都是極其有效的，就算對變異略有降低，還是有相當程度的效力。
引用:
….
Will the COVID-19 mRNA vaccines work against the new coronavirus variants?
Mutations have led to several new, concerning coronavirus variants, including the B.1.1.7 variant, which was first detected in the United Kingdom; the B.1.351 variant, which originated in South Africa; and the P.1 variant, which originated in Brazil. Emerging evidence suggests that the current mRNA vaccines are effective against at least some of these variants. Two peer-reviewed and published studies have found the Pfizer/BioNTech vaccine to be extremely effective against the B.1.1.7 and the B.1.351 variants. The first study, published in NEJM, looked at data from more than 200,000 people from the country of Qatar between early February and late March 2021. During that time, the B.1.1.7 and B.1.351 variants were responsible for nearly all COVID cases in that country. The researchers found that in people who were fully vaccinated, the Pfizer vaccine was 97.4% effective at preventing severe, critical, or fatal disease caused by the B.1.1.7 or B.1.351 variants.
The second study, published in The Lancet, looked at more than 200,000 COVID infections in Israel from late January to early April 2021, when the B.1.1.7 variant accounted for more than 90% of infections. The researchers found that in fully vaccinated people, the Pfizer vaccine was nearly 97% or more effective at preventing symptomatic COVID-19, COVID-related hospitalization, severe or critical COVID-19, or COVID-related death.
In the lab, the Moderna vaccine has also performed well against the B.1.1.7 variant. However, it was less effective against the B.1.351 variant; in a laboratory study, the vaccine resulted in fewer neutralizing antibodies being produced against the B.1.351 variant, compared to the unmutated virus and the B.1.1.7 variant. More study is needed to see if the laboratory results hold up in real-world conditions.
Neither company has released data regarding the P.1 variant, which shares some of the same mutations as the B.1.351 variant.
Both Moderna and Pfizer/BioNTech have announced plans to study variant-specific vaccine boosters, designed to specifically target the B.1.351 variant. In addition, both companies are testing whether a third dose of their existing, FDA-authorized vaccines provides additional protection against variants of concern.
Early laboratory evidence suggests that antibodies created in response to both the Pfizer/BioNTech and Moderna mRNA vaccines are effective against another new variant known as the New York variant, or B.1.526.
It's important to remember that both the Pfizer/BioNTech and Moderna vaccines are extremely effective — 95% and 94.1%, respectively. Even with a drop in effectiveness, they will still provide protection.
….
|
|